HIV Exposure: Understanding Post-Exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is a 28-day course of antiretroviral drugs started urgently after potential HIV exposure to prevent establishment of infection. It is a medical emergency—every hour of delay reduces efficacy.
When to Initiate PEP
- Occupational: Needlestick, mucous membrane splash, non-intact skin contact with blood/body fluids from HIV+ or unknown status source.
- Non-occupational (nPEP): Sexual assault, condomless sex with HIV+ partner not virally suppressed, needle-sharing, other high-risk exposures.
Time window: Ideally ≤2 hours; up to 72 hours (3 days) post-exposure. After 72 hours, PEP is not recommended (insufficient evidence).
Risk Assessment (Determines Urgency)
| Exposure Type | Source HIV+ / VL Unknown | Source HIV+ / VL Undetectable |
|---|---|---|
| Receptive anal sex | Strongly recommend | Generally not needed (U=U) |
| Insertive anal sex | Recommend | Generally not needed |
| Receptive vaginal sex | Recommend | Generally not needed |
| Insertive vaginal sex | Consider | Generally not needed |
| Needle sharing | Strongly recommend | Consider |
| Needlestick (hollow bore) | Recommend | Consider |
| Splash to mucous membrane | Consider | Generally not needed |
Recommended Regimens (US CDC / WHO Guidelines)
Preferred (3-drug)
- Tenofovir DF 300 mg + Emtricitabine 200 mg (Truvada®) ONCE DAILY
PLUS Raltegravir 400 mg TWICE DAILY OR Dolutegravir 50 mg ONCE DAILY OR Darunavir 800 mg + Ritonavir 100 mg ONCE DAILY - Alternative: TAF/FTC (Descovy®) + DTG or RAL.
Special Populations
- Pregnancy: TDF/FTC + RAL (DTG neural tube defect concern at conception; safe after 1st trimester).
- Children: Weight-based dosing; DTG approved ≥4 weeks/≥3 kg.
- Renal impairment (eGFR <60): Avoid TDF; use TAF or ABC/3TC + DTG/RAL.
Accessing PEP
- Emergency Department: 24/7 access; starter packs often available.
- Sexual health / HIV clinics: Often same-day appointments.
- Occupational health: For workplace exposures.
- Telehealth: Increasingly available for nPEP initiation.
Follow-Up & Monitoring
- Baseline: HIV Ag/Ab, HIV RNA, renal/hepatic function, pregnancy test, STI screen.
- Adherence counseling: Critical for efficacy; manage nausea (common with DTG/RAL).
- 4–6 weeks: HIV test.
- 3 months: HIV test (definitive exclusion).
- 6 months: Optional if high-risk exposure or seroconversion symptoms.
Key Points
- PEP is not 100% effective; failure associated with delayed start, non-adherence, resistant virus, re-exposure.
- Side effects: GI upset, headache, fatigue; usually transient.
- Transition to PrEP if ongoing risk.
- Source testing: Rapid HIV test on source (if known) informs need for PEP continuation.
HIV & AIDS - Related Articles
- Understanding HIV Symptoms: Early Signs & What to Do
- HIV Treatment and Research: Current Therapies and Future Prospects
- Asymptomatic HIV: Understanding the Silent Stage, Testing, and Prevention
- Pneumonia and AIDS: Understanding the Increased Risk
- Understanding Second-Line HIV Treatment: What You Need to Know
- Traveling with HIV: Essential Health & Safety Tips
- Understanding AIDS Symptoms: Early & Advanced Signs
